Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Protective Efficacy of Nucleic Acid Vaccines Against Transmission of Zika Virus During Pregnancy in Mice.

Jagger BW, Dowd KA, Chen RE, Desai P, Foreman B, Burgomaster KE, Himansu S, Kong WP, Graham BS, Pierson TC, Diamond MS.

J Infect Dis. 2019 Jul 1. pii: jiz338. doi: 10.1093/infdis/jiz338. [Epub ahead of print]

PMID:
31260518
2.

Effects of dengue immunity on Zika virus infection.

Whitehead SS, Pierson TC.

Nature. 2019 Mar;567(7749):467-468. doi: 10.1038/d41586-019-00868-6. No abstract available.

PMID:
30911157
3.

Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice.

Salazar V, Jagger BW, Mongkolsapaya J, Burgomaster KE, Dejnirattisai W, Winkler ES, Fernandez E, Nelson CA, Fremont DH, Pierson TC, Crowe JE Jr, Screaton GR, Diamond MS.

Cell Rep. 2019 Feb 5;26(6):1585-1597.e4. doi: 10.1016/j.celrep.2019.01.052.

4.

An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections.

VanBlargan LA, Himansu S, Foreman BM, Ebel GD, Pierson TC, Diamond MS.

Cell Rep. 2018 Dec 18;25(12):3382-3392.e3. doi: 10.1016/j.celrep.2018.11.082.

5.

A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.

Goo L, Debbink K, Kose N, Sapparapu G, Doyle MP, Wessel AW, Richner JM, Burgomaster KE, Larman BC, Dowd KA, Diamond MS, Crowe JE Jr, Pierson TC.

Nat Microbiol. 2019 Jan;4(1):71-77. doi: 10.1038/s41564-018-0283-7. Epub 2018 Nov 19.

6.

Cross-Reactive Flavivirus Antibody: Friend and Foe?

Maciejewski S, Pierson TC.

Cell Host Microbe. 2018 Nov 14;24(5):622-624. doi: 10.1016/j.chom.2018.10.016.

PMID:
30439339
7.

Zika Virus Vaccine Development: Progress in the Face of New Challenges.

Diamond MS, Ledgerwood JE, Pierson TC.

Annu Rev Med. 2019 Jan 27;70:121-135. doi: 10.1146/annurev-med-040717-051127. Epub 2018 Nov 2.

PMID:
30388054
8.

The Many Faces of a Dynamic Virion: Implications of Viral Breathing on Flavivirus Biology and Immunogenicity.

Dowd KA, Pierson TC.

Annu Rev Virol. 2018 Sep 29;5(1):185-207. doi: 10.1146/annurev-virology-092917-043300. Review.

PMID:
30265634
9.

The emergence of Zika virus and its new clinical syndromes.

Pierson TC, Diamond MS.

Nature. 2018 Aug;560(7720):573-581. doi: 10.1038/s41586-018-0446-y. Epub 2018 Aug 29. Review.

PMID:
30158602
10.

A VSV-based Zika virus vaccine protects mice from lethal challenge.

Emanuel J, Callison J, Dowd KA, Pierson TC, Feldmann H, Marzi A.

Sci Rep. 2018 Jul 23;8(1):11043. doi: 10.1038/s41598-018-29401-x.

11.

Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Frei JC, Wirchnianski AS, Govero J, Vergnolle O, Dowd KA, Pierson TC, Kielian M, Girvin ME, Diamond MS, Lai JR.

J Virol. 2018 Aug 29;92(18). pii: e01023-18. doi: 10.1128/JVI.01023-18. Print 2018 Sep 15.

12.

The Zika virus envelope protein glycan loop regulates virion antigenicity.

Goo L, DeMaso CR, Pelc RS, Ledgerwood JE, Graham BS, Kuhn RJ, Pierson TC.

Virology. 2018 Feb;515:191-202. doi: 10.1016/j.virol.2017.12.032. Epub 2018 Jan 2.

13.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE, Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR, Graham BS, Pierson TC, Ledgerwood JE, Chen GL; VRC 319; VRC 320 study teams.

Lancet. 2018 Feb 10;391(10120):552-562. doi: 10.1016/S0140-6736(17)33105-7. Epub 2017 Dec 5.

14.

A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage.

Shan C, Muruato AE, Jagger BW, Richner J, Nunes BTD, Medeiros DBA, Xie X, Nunes JGC, Morabito KM, Kong WP, Pierson TC, Barrett AD, Weaver SC, Rossi SL, Vasconcelos PFC, Graham BS, Diamond MS, Shi PY.

Nat Commun. 2017 Sep 22;8(1):676. doi: 10.1038/s41467-017-00737-8.

15.

Inhibitors of the Histone Methyltransferases EZH2/1 Induce a Potent Antiviral State and Suppress Infection by Diverse Viral Pathogens.

Arbuckle JH, Gardina PJ, Gordon DN, Hickman HD, Yewdell JW, Pierson TC, Myers TG, Kristie TM.

MBio. 2017 Aug 15;8(4). pii: e01141-17. doi: 10.1128/mBio.01141-17.

16.

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease.

Richner JM, Jagger BW, Shan C, Fontes CR, Dowd KA, Cao B, Himansu S, Caine EA, Nunes BTD, Medeiros DBA, Muruato AE, Foreman BM, Luo H, Wang T, Barrett AD, Weaver SC, Vasconcelos PFC, Rossi SL, Ciaramella G, Mysorekar IU, Pierson TC, Shi PY, Diamond MS.

Cell. 2017 Jul 13;170(2):273-283.e12. doi: 10.1016/j.cell.2017.06.040.

17.

Modified mRNA Vaccines Protect against Zika Virus Infection.

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS.

Cell. 2017 Mar 23;169(1):176. doi: 10.1016/j.cell.2017.03.016. No abstract available.

18.

Modified mRNA Vaccines Protect against Zika Virus Infection.

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS.

Cell. 2017 Mar 9;168(6):1114-1125.e10. doi: 10.1016/j.cell.2017.02.017. Epub 2017 Feb 17. Erratum in: Cell. 2017 Mar 23;169(1):176.

19.

A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis.

Goo L, VanBlargan LA, Dowd KA, Diamond MS, Pierson TC.

PLoS Pathog. 2017 Feb 16;13(2):e1006178. doi: 10.1371/journal.ppat.1006178. eCollection 2017 Feb.

20.

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.

Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D.

Nature. 2017 Mar 9;543(7644):248-251. doi: 10.1038/nature21428. Epub 2017 Feb 2.

21.

T Cells Take on Zika Virus.

Hickman HD, Pierson TC.

Immunity. 2017 Jan 17;46(1):13-14. doi: 10.1016/j.immuni.2016.12.020.

22.

A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.

Goo L, Dowd KA, Lin TY, Mascola JR, Graham BS, Ledgerwood JE, Pierson TC.

J Infect Dis. 2016 Nov 15;214(10):1487-1491. Epub 2016 Sep 21.

23.

Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

VanBlargan LA, Goo L, Pierson TC.

Microbiol Mol Biol Rev. 2016 Oct 26;80(4):989-1010. Print 2016 Dec. Review.

24.

Zika Virus: Immunity and Vaccine Development.

Pierson TC, Graham BS.

Cell. 2016 Oct 20;167(3):625-631. doi: 10.1016/j.cell.2016.09.020. Epub 2016 Sep 29. Review.

25.

Rapid development of a DNA vaccine for Zika virus.

Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, Gordon DN, Gallagher JR, Chen X, Todd JP, Tsybovsky Y, Harris A, Huang YS, Higgs S, Vanlandingham DL, Andersen H, Lewis MG, De La Barrera R, Eckels KH, Jarman RG, Nason MC, Barouch DH, Roederer M, Kong WP, Mascola JR, Pierson TC, Graham BS.

Science. 2016 Oct 14;354(6309):237-240. Epub 2016 Sep 22.

26.

Zika Virus Is Not Uniquely Stable at Physiological Temperatures Compared to Other Flaviviruses.

Goo L, Dowd KA, Smith AR, Pelc RS, DeMaso CR, Pierson TC.

MBio. 2016 Sep 6;7(5). pii: e01396-16. doi: 10.1128/mBio.01396-16.

27.

VIROLOGY. Diagnostics for Zika virus on the horizon.

Speer SD, Pierson TC.

Science. 2016 Aug 19;353(6301):750-1. doi: 10.1126/science.aah6187. No abstract available.

PMID:
27540152
28.

Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype.

Dowd KA, DeMaso CR, Pelc RS, Speer SD, Smith ARY, Goo L, Platt DJ, Mascola JR, Graham BS, Mulligan MJ, Diamond MS, Ledgerwood JE, Pierson TC.

Cell Rep. 2016 Aug 9;16(6):1485-1491. doi: 10.1016/j.celrep.2016.07.049. Epub 2016 Jul 29.

29.

Structural Basis of Zika Virus-Specific Antibody Protection.

Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J, Nelson CA, Pierson TC, Diamond MS, Fremont DH.

Cell. 2016 Aug 11;166(4):1016-1027. doi: 10.1016/j.cell.2016.07.020. Epub 2016 Jul 27.

30.

Enhancing dengue virus maturation using a stable furin over-expressing cell line.

Mukherjee S, Sirohi D, Dowd KA, Chen Z, Diamond MS, Kuhn RJ, Pierson TC.

Virology. 2016 Oct;497:33-40. doi: 10.1016/j.virol.2016.06.022. Epub 2016 Jul 13.

31.

A CRISPR screen defines a signal peptide processing pathway required by flaviviruses.

Zhang R, Miner JJ, Gorman MJ, Rausch K, Ramage H, White JP, Zuiani A, Zhang P, Fernandez E, Zhang Q, Dowd KA, Pierson TC, Cherry S, Diamond MS.

Nature. 2016 Jul 7;535(7610):164-8. Epub 2016 Jun 17.

32.

Zika in the Brain: New Models Shed Light on Viral Infection.

Hickman HD, Pierson TC.

Trends Mol Med. 2016 Aug;22(8):639-641. doi: 10.1016/j.molmed.2016.06.004. Epub 2016 Jun 23. Review.

33.

The 3.8 Å resolution cryo-EM structure of Zika virus.

Sirohi D, Chen Z, Sun L, Klose T, Pierson TC, Rossmann MG, Kuhn RJ.

Science. 2016 Apr 22;352(6284):467-70. doi: 10.1126/science.aaf5316. Epub 2016 Mar 31.

34.
35.

Dengue viruses cluster antigenically but not as discrete serotypes.

Katzelnick LC, Fonville JM, Gromowski GD, Bustos Arriaga J, Green A, James SL, Lau L, Montoya M, Wang C, VanBlargan LA, Russell CA, Thu HM, Pierson TC, Buchy P, Aaskov JG, Muñoz-Jordán JL, Vasilakis N, Gibbons RV, Tesh RB, Osterhaus AD, Fouchier RA, Durbin A, Simmons CP, Holmes EC, Harris E, Whitehead SS, Smith DJ.

Science. 2015 Sep 18;349(6254):1338-43. doi: 10.1126/science.aac5017.

36.

Dengue virus: Bumps in the road to therapeutic antibodies.

Goo L, Pierson TC.

Nature. 2015 Aug 20;524(7565):295-6. doi: 10.1038/524295a. No abstract available.

PMID:
26289200
37.

Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control.

Diamond MS, Pierson TC.

Cell. 2015 Jul 30;162(3):488-92. doi: 10.1016/j.cell.2015.07.005. Review.

38.

Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly.

VanBlargan LA, Davis KA, Dowd KA, Akey DL, Smith JL, Pierson TC.

J Virol. 2015 Aug;89(16):8632-42. doi: 10.1128/JVI.01253-15. Epub 2015 Jun 10.

39.

Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host.

Kuhn RJ, Dowd KA, Beth Post C, Pierson TC.

Virology. 2015 May;479-480:508-17. doi: 10.1016/j.virol.2015.03.025. Epub 2015 Mar 30. Review.

40.

A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection.

Pierson TC, Diamond MS.

Prog Mol Biol Transl Sci. 2015;129:141-66. doi: 10.1016/bs.pmbts.2014.10.005. Epub 2014 Dec 1. Review.

41.

Vaccine Development as a Means to Control Dengue Virus Pathogenesis: Do We Know Enough?

Pierson TC, Diamond MS.

Annu Rev Virol. 2014 Nov;1(1):375-98. doi: 10.1146/annurev-virology-031413-085453. Epub 2014 Jun 27.

PMID:
26958727
42.

Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.

Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz RM, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE; VRC 311 Study Team.

Lancet. 2014 Dec 6;384(9959):2046-52. doi: 10.1016/S0140-6736(14)61185-5. Epub 2014 Aug 14.

PMID:
25132507
43.

Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition.

Dowd KA, Mukherjee S, Kuhn RJ, Pierson TC.

J Virol. 2014 Oct;88(20):11726-37. doi: 10.1128/JVI.01140-14. Epub 2014 Jul 30.

44.

Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.

Edeling MA, Austin SK, Shrestha B, Dowd KA, Mukherjee S, Nelson CA, Johnson S, Mabila MN, Christian EA, Rucker J, Pierson TC, Diamond MS, Fremont DH.

PLoS Pathog. 2014 Apr 17;10(4):e1004072. doi: 10.1371/journal.ppat.1004072. eCollection 2014 Apr.

45.

Mechanism and significance of cell type-dependent neutralization of flaviviruses.

Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC.

J Virol. 2014 Jul;88(13):7210-20. doi: 10.1128/JVI.03690-13. Epub 2014 Apr 16.

46.

Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection.

Mukherjee S, Pierson TC, Dowd KA.

Methods Mol Biol. 2014;1138:75-97. doi: 10.1007/978-1-4939-0348-1_6.

PMID:
24696332
47.

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2013;9(12):e1003761. doi: 10.1371/journal.ppat.1003761. Epub 2013 Dec 5.

48.

The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, Diamond MS, Fremont DH, Pierson TC.

J Virol. 2013 Dec;87(24):13729-40. doi: 10.1128/JVI.02340-13. Epub 2013 Oct 9.

49.

Nucleolin interacts with the dengue virus capsid protein and plays a role in formation of infectious virus particles.

Balinsky CA, Schmeisser H, Ganesan S, Singh K, Pierson TC, Zoon KC.

J Virol. 2013 Dec;87(24):13094-106. doi: 10.1128/JVI.00704-13. Epub 2013 Sep 11.

50.

Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2013 Aug;87(16):8826-42. doi: 10.1128/JVI.01314-13. Epub 2013 Jun 19.

Supplemental Content

Loading ...
Support Center